Weekly update|Companies|Recruiting|Promote|Post a job

RayzeBio

Founded: 2020

Location: San Diego, CA

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: neuroendocrine tumors

Drug types: ONC

Lead product: RYZ101

Product link: https://rayzebio.com/pipeline/pipeline-overview/

Funding: $160M D Sep 2022; $108M C Jun 2021; $105M B Dec 2020; $45M A Oct 2020

Investors: Versant, VenBio, Samsara BioCapital, Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital

rayzebio.com

linkedin.com

job board

Short description:

Radiopharmaceuticals Therapy for Cancer

Drug notes:

Also Clin1 SCLC; Glypican-3 Clin0 Liver Cancer; 5 add'l RD programs solid tumors

Long description:

RayzeBio is developing radiopharmaceuticals for cancer treatment. Radiopharmaceutical therapy (RPT) represents a promising novel approach to treat solid tumors. RPT works by selectively delivering radioisotopes to tumors via the bloodstream. Rayze is focusing on alpha and beta radioisotopes, with a preference for using Actinium 225, an alpha radioisotope for therapeutic programs. Importantly, Rayze is also focused on optimizing their target selection and their molecular binders such that the therapies can be agile to allow for deep tumor penetration and be tunable to create drug-like properties for proper clearance from the bloodstream.